# 4538
CIDRAP (Center For Infectious Disease Research & Policy) presents the third in a series of Lessons Learned reports – written this time by Lisa Schnirring – focusing on the pandemic vaccination campaign.
I blogged on the first two reports at:
CIDRAP: H1N1 Lessons Learned
CIDRAP’s Lessons Learned: Pt II
As always with a CIDRAP report, this is well worth following the link and reading in its entirety.
H1N1 LESSONS LEARNED
Vaccination campaign weathered rough road, paid dividendsLisa Schnirring
Staff Writer
This is the third in a series of reports marking the first anniversary of novel H1N1 pandemic influenza. The first and second articles appeared on Apr 23 and Apr 26.
Apr 30, 2010 (CIDRAP News) – As the biggest public health initiative in the history of the US Centers for Disease Control and Prevention (CDC), the H1N1 pandemic vaccination campaign encountered stiff headwinds with scarce supplies and complex messaging but ended up reaching about a quarter of the US population and, some say, smoothing the path for future immunization efforts.
About a month after the pandemic flu virus emerged, federal officials ordered vaccines from five different companies at a price tag of $650 million, with $287million more for adjuvants that could be needed if the virus turned out to be severe or if vaccine potency was lower than expected.
